EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Pell Bio-Med Technology Co., Ltd. (6949) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Pell Bio-Med Technology Co., Ltd. TWD 9.78, price TWD 44.50, upside -78.0%, quality 29 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · TW

PB Thin data Sep 24, 2026

Pell Bio-Med Technology Co., Ltd.

6949 · TW

Weakest SetupStrongly overvalued and low quality.

!Fair value 9.78 TWD · Strongly overvalued (−78.0%)
!Quality 29/100
!Expensive Growth (revenue 3y +22.4 %/yr)
!negative free cash flow
!Trails peers (0/5)
!Narrow moat 16/100
!Evidence only low, so the estimate is less certain
Watch Pell Bio-Med Technology Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

1,490 TWD 44.50 TWD Fair Value 9.78 TWD Mar 2024 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

31‑month range 44.50 TWD – 1,490 TWD · fair‑value band 6.46 TWD – 12.23 TWD · the 44.50 TWD price screens above the 9.78 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Pell Bio-Med Technology Co. in your weekly email

Every Wednesday you see whether Pell Bio-Med Technology Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of chimeric antigen recombinant T cell (CAR-T), and other related services and products.

Show more

Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of chimeric antigen recombinant T cell (CAR-T), and other related services and products. It offers autologous adipose-derived stem cell (ADSC) products to treat osteoarthritis and cartilage defects in the knee; cytokine-induced Killer cells to treat various tumors; and dendritic cell-activated cytokine-induced killer to treat solid tumors. The company is also involved in the phase 1/2 multicenter study to evaluate the safety and efficacy of CD19-targeted chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell lymphoma; a follow-up study of lentiviral-based gene-modified immune cell therapy. The company was founded in 2017 and is based in Taipei, Taiwan.

Stock analysis

Pell Bio-Med Technology Co., Ltd. (6949) currently trades at 44.50 TWD, while our model-based Fair Value estimate is 9.78 TWD, 78.0% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 80/100, which puts the evidence level at low.

Scenario range: 6.46 TWD (bear) to 12.23 TWD (bull), the price of 44.50 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Pell Bio-Med Technology Co., Ltd. reported revenue of 31.4M TWD in FY2025 versus 14.0M TWD in FY2021, a compound +22.5%/yr. Reported net income was −453M TWD in FY2025.

Key figures

Market cap 65.9B TWD (≈ $2.1B) · EPS (TTM) −7.07 TWD · Return on equity −22.3% · Return on assets (EBIT) −29.4% · Operating margin −1,394% · Revenue (TTM) 25.8M TWD · Revenue growth (YoY) −46.7% · Free cash flow −509M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).

What moves the price

The share trades about 97% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −78%, 6949 screens richer than that median.

Fair Value models

Bear 6.46 TWD Fair Value 9.78 TWD Bull 12.23 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 10.85 TWD 14.54 TWD 21.69 TWD 51
All 1 models by family
Asset-Based
NCAV (Graham) 10.85 TWD 14.54 TWD 21.69 TWD 51

Open the full fair value analysis →

Notify me when 6949 reaches fair value

Put 6949 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 29/100

Of which business quality 33 · Market factors (momentum, volatility) 10

Profitability 0
Margins and returns on capital today
Quality Growth 82
Are margins and returns improving?
Cashflow 3
Earnings quality: real cash, not paper profit
Fin. Strength 86
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 34
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 26
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+60.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,402.0% (2021) → −1,487.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6949 screens overvalued: fair value 78% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Pell Bio-Med Technology Co., Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 624 stocks

Beats the industry median on 0/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 33 · Below median
Fair Value upside −78.0% · Bottom 25%
Profitability
Return on assets −11.9% · Below median
Growth and dividend
Revenue growth −46.7% · Bottom 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pell Bio-Med Technology Co., Ltd. · Fair Value
9.78 TWD −78%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Pell Bio-Med Technology Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/6949

Frequently asked questions

Is Pell Bio-Med Technology Co., Ltd. (6949) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 9.78 TWD versus a price of 44.50 TWD, about −78% upside (overvalued).
What is the fair value of 6949?
Our model-based fair value for Pell Bio-Med Technology Co., Ltd. is 9.78 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 44.50 TWD.
What is the quality score of 6949?
Pell Bio-Med Technology Co., Ltd. has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pell Bio-Med Technology Co., Ltd. (6949)?
Our model-based price target is the fair value of 9.78 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 6.46 TWD, optimistic scenario 12.23 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Pell Bio-Med Technology Co., Ltd. stock forecast for 2026?
Our models put fair value at 9.78 TWD, about −78% upside versus a price of 44.50 TWD (overvalued). Cautious scenario 6.46 TWD, optimistic scenario 12.23 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Pell Bio-Med Technology Co., Ltd. (6949)?
Pell Bio-Med Technology Co., Ltd. reported trailing-twelve-month revenue of about 25.8M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Pell Bio-Med Technology Co., Ltd. (6949)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pell Bio-Med Technology Co., Ltd. it is 9.78 TWD per share (as of Sep 24, 2026), against a price of 44.50 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Pell Bio-Med Technology Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6949 trades above its calculated fair value: price 44.50 TWD, fair value 9.78 TWD, a gap of about −78% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6949?
No. The price is what the market pays today (44.50 TWD); the fair value is what the company's own numbers justify (9.78 TWD). For Pell Bio-Med Technology Co., Ltd. the two are 34.72 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Pell Bio-Med Technology Co., Ltd. worth?
The market values Pell Bio-Med Technology Co., Ltd. at about 65.9B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 44.50 TWD; our models calculate a fair value of 9.78 TWD per share.
What do the bullish and bearish scenarios say about 6949?
Our models span a range for Pell Bio-Med Technology Co., Ltd.: cautious scenario 6.46 TWD, base 9.78 TWD, optimistic 12.23 TWD per share (as of Sep 24, 2026, price 44.50 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pell Bio-Med Technology Co., Ltd. (6949)?
Balance-sheet figures for Pell Bio-Med Technology Co., Ltd. (as of Sep 24, 2026): return on equity −22.3%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is 6949 from its 52-week high?
Pell Bio-Med Technology Co., Ltd. trades at 44.50 TWD, about 97% below its 52-week high of 1,490 TWD and at the low of 44.50 TWD (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 9.78 TWD is for.
Which stocks are comparable to Pell Bio-Med Technology Co., Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pell Bio-Med Technology Co., Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 44.50 TWD, calculated fair value 9.78 TWD (−78%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6949 calculated?
We run Pell Bio-Med Technology Co., Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 9.78 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Pell Bio-Med Technology Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pell Bio-Med Technology Co., Ltd. (6949)?
The closing price on Oct 2, 2026 was 44.50 TWD. Our model-based fair value is 9.78 TWD, about −78% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pell Bio-Med Technology Co., Ltd. right now?
The price sits above even our optimistic bull case (12.23 TWD). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (6.46 TWD to 12.23 TWD) leaves room in how you read the outcome.

Key figures of Pell Bio-Med Technology Co., Ltd.

How large is the market capitalisation of Pell Bio-Med Technology Co., Ltd. (6949)?
The market capitalisation of Pell Bio-Med Technology Co., Ltd. is 65.9B TWD (≈ $2.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Pell Bio-Med Technology Co., Ltd. (6949)?
Earnings per share at Pell Bio-Med Technology Co., Ltd. are −7.07 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Pell Bio-Med Technology Co., Ltd. (6949)?
The return on equity (ROE) of Pell Bio-Med Technology Co., Ltd. is −22.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pell Bio-Med Technology Co., Ltd. (6949)?
On an EBIT basis the return on assets of Pell Bio-Med Technology Co., Ltd. is −29.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pell Bio-Med Technology Co., Ltd. (6949)?
The operating margin of Pell Bio-Med Technology Co., Ltd. is −1,394% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pell Bio-Med Technology Co., Ltd. (6949)?
Revenue at Pell Bio-Med Technology Co., Ltd. is growing −46.7% versus a year earlier (3y avg +22.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Pell Bio-Med Technology Co., Ltd. (6949) generate?
The free cash flow of Pell Bio-Med Technology Co., Ltd. is −509M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Pell Bio-Med Technology Co., Ltd. (6949) hold?
Pell Bio-Med Technology Co., Ltd. holds more cash than debt, 69.3M TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Pell Bio-Med Technology Co., Ltd. in the live analysis

One click puts Pell Bio-Med Technology Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.